JP7486953B2 - 細胞標的化療法のための組成物および方法 - Google Patents

細胞標的化療法のための組成物および方法 Download PDF

Info

Publication number
JP7486953B2
JP7486953B2 JP2019563540A JP2019563540A JP7486953B2 JP 7486953 B2 JP7486953 B2 JP 7486953B2 JP 2019563540 A JP2019563540 A JP 2019563540A JP 2019563540 A JP2019563540 A JP 2019563540A JP 7486953 B2 JP7486953 B2 JP 7486953B2
Authority
JP
Japan
Prior art keywords
cells
cell
rhob
tcr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520367A (ja
JP2020520367A5 (https=
Inventor
クボール，ユルゲン・ヘルベルト・エルンスト
セバスティヤン，ジョルト
ベリンジャー，デニス
ヴィボロバ，アンナ
Original Assignee
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーエムセー・ユトレヒト・ホールディング・ベー・フェー filed Critical ユーエムセー・ユトレヒト・ホールディング・ベー・フェー
Publication of JP2020520367A publication Critical patent/JP2020520367A/ja
Publication of JP2020520367A5 publication Critical patent/JP2020520367A5/ja
Application granted granted Critical
Publication of JP7486953B2 publication Critical patent/JP7486953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019563540A 2017-05-18 2018-05-18 細胞標的化療法のための組成物および方法 Active JP7486953B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762508272P 2017-05-18 2017-05-18
US62/508,272 2017-05-18
US201762508833P 2017-05-19 2017-05-19
US62/508,833 2017-05-19
PCT/EP2018/063210 WO2018211115A1 (en) 2017-05-18 2018-05-18 Compositions and methods for cell targeting therapies

Publications (3)

Publication Number Publication Date
JP2020520367A JP2020520367A (ja) 2020-07-09
JP2020520367A5 JP2020520367A5 (https=) 2023-04-18
JP7486953B2 true JP7486953B2 (ja) 2024-05-20

Family

ID=62492593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563540A Active JP7486953B2 (ja) 2017-05-18 2018-05-18 細胞標的化療法のための組成物および方法

Country Status (7)

Country Link
US (1) US12161669B2 (https=)
EP (1) EP3624823A1 (https=)
JP (1) JP7486953B2 (https=)
CN (1) CN110944658A (https=)
AU (1) AU2018268087B2 (https=)
CA (1) CA3063807A1 (https=)
WO (1) WO2018211115A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334741B (zh) 2012-03-28 2018-08-17 歌德塔有限公司 组合的γ9δ2T细胞受体链交换
EP4099015A1 (en) 2016-06-10 2022-12-07 Gadeta B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
EP3624823A1 (en) 2017-05-18 2020-03-25 UMC Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2019156566A1 (en) * 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019219979A1 (en) * 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
EP4267604A1 (en) 2020-12-23 2023-11-01 Gadeta B.V. Chimeric, transmembrane proteins with bidirectional signalling activity
CN112255395B (zh) * 2020-12-23 2021-06-18 中生北控生物科技股份有限公司 一种消除脂血样本中乳糜干扰的方法和免疫浊度法试剂盒及应用
EP4288074A4 (en) * 2021-02-08 2025-04-30 The Regents of University of California Regulation of butvrophilin subfamily 3 member a1 (btn3a1, cd277)
AU2022241654A1 (en) * 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
WO2022214707A1 (en) 2021-04-09 2022-10-13 Gadeta B.V. Cellular reporter and methods of using the same
WO2023242434A1 (en) 2022-06-17 2023-12-21 Gadeta B.V. Modified immune cells
GB202406837D0 (en) * 2024-05-14 2024-06-26 Immunocore Ltd Screening methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520223A (ja) 2004-11-23 2008-06-19 メディジーン リミテッド ガンマ−デルタｔ細胞レセプター
JP2015513900A (ja) 2012-03-28 2015-05-18 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー コンビナトリアルガンマ９デルタ２ｔ細胞レセプター鎖交換
US20150353643A1 (en) 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
JP2016501013A (ja) 2012-11-08 2016-01-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
WO2016125757A1 (ja) 2015-02-02 2016-08-11 国立大学法人 長崎大学 新規フッ素含有型ビスホスホン酸誘導体及びその用途
WO2016166544A1 (en) 2015-04-15 2016-10-20 Tc Biopharm Ltd Modified gamma delta cells and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
IL132463A0 (en) 1997-05-13 2001-03-19 Univ North Carolina Lentivirus - based gene transfer vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
GB9810099D0 (en) 1998-05-11 1998-07-08 Isis Innovation Novel molecule and diagnostic method
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2001332430A (ja) 2000-05-22 2001-11-30 Murata Mfg Co Ltd トランス
AU2001292842A1 (en) 2000-09-19 2002-04-02 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
CN1280307C (zh) 2001-04-03 2006-10-18 宝生物工程株式会社 细胞毒性t淋巴细胞
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
CA2513013A1 (en) 2002-01-10 2003-07-24 National Jewish Medical And Research Center Use of soluble .gamma..delta. t cell receptors for regulating t cell function
MXPA05001933A (es) 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4516916B2 (ja) 2003-07-11 2010-08-04 昇志 佐藤 リビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
GB0506760D0 (en) 2005-04-01 2005-05-11 Avidex Ltd High affinity HIV TCRS
PT1956080E (pt) 2005-08-08 2011-12-30 San Raffaele Centro Fond Uso de il-7 e il-15 para a modificação genética de linfócitos t da memória
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US20090075378A1 (en) 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
US8603810B2 (en) 2008-05-09 2013-12-10 Agency For Science, Technology And Research T-cell having a T-cell receptor that recognizes epitope HBC18-27 of hepatitis B viral core antigen
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
WO2010087335A1 (ja) 2009-01-27 2010-08-05 学校法人産業医科大学 Ｔ細胞抗原受容体遺伝子、受容体α鎖及びβ鎖発現用ベクター並びに細胞障害性Ｔ細胞
DK3246042T3 (da) 2009-11-02 2019-10-14 Univ Emory Lægemiddelresistent immunterapi til behandling af cancer
CN102453701B (zh) 2010-10-26 2014-08-13 中国医学科学院基础医学研究所 基因修饰CDR3δ移植型γδT淋巴细胞及其抑癌用途
KR101551555B1 (ko) 2011-03-17 2015-09-08 밀테니 비오텍 게앰베하 Tcr 알파/베타가 고갈된 세포 제제
CN102532269B (zh) 2011-05-16 2014-07-09 中国医学科学院基础医学研究所 γδT淋巴细胞中δ1链互补决定域3的优势序列及其TCR受体转染细胞与应用
PT2710123T (pt) 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2014179202A1 (en) 2013-05-02 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
WO2015063069A1 (en) 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
US11203783B2 (en) 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
AU2015214145A1 (en) 2014-02-04 2016-08-25 Kite Pharma. Inc. Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
WO2016195086A1 (ja) 2015-06-05 2016-12-08 医療法人社団 滉志会 アレルギー性疾患の治療薬
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
CA2996887A1 (en) 2015-09-11 2017-03-16 Agenus Inc. Engineered host cells and methods of use thereof
CN105296431B (zh) 2015-11-26 2018-10-09 北京佳德和细胞治疗技术有限公司 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途
US12297427B2 (en) 2015-12-04 2025-05-13 St. Jude Children's Research Hospital, Inc. Cloning and expression system for T-cell receptors
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
EP4099015A1 (en) 2016-06-10 2022-12-07 Gadeta B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
AU2018231405B2 (en) 2017-03-07 2024-02-08 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
EP3624823A1 (en) 2017-05-18 2020-03-25 UMC Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520223A (ja) 2004-11-23 2008-06-19 メディジーン リミテッド ガンマ−デルタｔ細胞レセプター
JP2015513900A (ja) 2012-03-28 2015-05-18 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー コンビナトリアルガンマ９デルタ２ｔ細胞レセプター鎖交換
JP2016501013A (ja) 2012-11-08 2016-01-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
US20150353643A1 (en) 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
WO2016125757A1 (ja) 2015-02-02 2016-08-11 国立大学法人 長崎大学 新規フッ素含有型ビスホスホン酸誘導体及びその用途
WO2016166544A1 (en) 2015-04-15 2016-10-20 Tc Biopharm Ltd Modified gamma delta cells and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zsolt Sebestyen et al.，RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor，Cell Reports，Volume 15, Issue 9，Pages 1973-1985，https://doi.org/10.1016/j.celrep.2016.04.081

Also Published As

Publication number Publication date
AU2018268087B2 (en) 2022-03-17
JP2020520367A (ja) 2020-07-09
EP3624823A1 (en) 2020-03-25
WO2018211115A1 (en) 2018-11-22
AU2018268087A1 (en) 2020-01-02
CA3063807A1 (en) 2018-11-22
CN110944658A (zh) 2020-03-31
US20200368278A1 (en) 2020-11-26
US12161669B2 (en) 2024-12-10

Similar Documents

Publication Publication Date Title
JP7486953B2 (ja) 細胞標的化療法のための組成物および方法
JP7742773B2 (ja) Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
US20230248770A1 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
US10479997B2 (en) Compositions and methods for diagnosis and treatment of prostate cancer
JP7510413B2 (ja) Ｂ細胞成熟抗原に特異的なキメラ抗原受容体を使用する処置方法
CN107075482B (zh) 使用抗cd19嵌合抗原受体治疗癌症
US20210396739A1 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
KR20220104217A (ko) Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
CN110997920A (zh) 新型细胞标签的表达
US20220249637A1 (en) Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
JP2017500869A (ja) ヒトメソテリンキメラ抗原受容体およびその使用
WO2019219979A1 (en) Compositions and methods for cell targeting therapies
JP2024502479A (ja) キメラ受容体療法
US12031975B2 (en) Methods of assessing or monitoring a response to a cell therapy
RU2796334C9 (ru) Экспрессия новых клеточных меток
RU2796334C2 (ru) Экспрессия новых клеточных меток
KR20260051061A (ko) Cd19-표적화 car t 세포 요법
WO2026033136A1 (en) Advanced treatment modalities for anti-prame tcr-engineered immune cells
HK40111761A (zh) 嵌合受体疗法
JP2024513843A (ja) 腫瘍抗原を標的とするための方法および材料
EA041126B1 (ru) Антитела и полипептиды, направленные против cd127

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240508

R150 Certificate of patent or registration of utility model

Ref document number: 7486953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150